Lonza Biologics Inc.

ToolGen has filed a patent infringement lawsuit in the Netherlands against Lonza, alleging unauthorized use of its CRISPR-Cas9 RNP technology in producing CASGEVY, the world's first approved gene-editing therapy.

Lonza, Excellos, and Akadeum Life Sciences have announced a collaborative project aimed at redefining cell therapy manufacturing standards by focusing on starting material quality and integrated workflows.

The FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to Galapagos' GLPG5101, a second-generation anti-CD19/4-1BB CAR-T therapy for relapsed/refractory mantle cell lymphoma.

Akadeum Life Sciences closed a $20 million+ financing round led by Michigan Capital Network to scale commercial operations and support customers entering clinical trials.

The antibody-drug conjugate (ADC) market in non-small-cell lung cancer is projected to grow at a 6.8% CAGR across seven major markets and exceed $3.9 billion by 2032.

Ethris has secured $5 million in funding from CEPI to advance the development of spray-dried RNA vaccines that remain stable at room temperature and are suitable for mucosal delivery.

Ethris and Lonza have formed a strategic partnership to develop spray-dried mRNA vaccines for respiratory diseases that remain stable at room temperature, eliminating cold chain requirements.

Swiss-based Debiopharm and French CRO Oncodesign Services have established a license agreement for AbYlink™, a regio-selective bioconjugation technology designed for therapeutic and non-invasive diagnostic applications.

Korean biotech company ToolGen has filed patent infringement lawsuits against Vertex Pharmaceuticals in the UK and Netherlands over the world's first approved CRISPR gene therapy, Casgevy.

Galapagos's lead CD19 CAR-T candidate GLPG5101 demonstrated compelling clinical results across three non-Hodgkin lymphoma indications, with complete response rates of 100% in MCL and 95% in MZL/FL.